Recently, the results of China's Top 10 Pharmaceutical Biotechnology Advances in 2024 were announced in Xiamen. The P85-Ab Nasopharyngeal Cancer Early Diagnosis Kit—the EBV BNLF2b Antibody Detection Kit (Magnetic Microparticle Chemiluminescence), jointly developed by the Ningshao Xia’s team from Xiang An Biomedine Laboratory of Xiamen University, and WAITAl BioPharm, has been approved for market launch and selected as one of the China's Top 10 Pharmaceutical Biotechnology Advances in 2024.

The nasopharyngeal cancer early diagnosis kit utilizes the world's first serological biomarkers of nasopharyngeal cancer, discovered by Xiamen University: the anti-BNLF2b total antibody (P85-Ab). In a large-scale prospective nasopharyngeal cancer screening cohort study, the kit demonstrated a sensitivity of 97.9% and a specificity of 98.3%. Compared to existing screening methods, the early detection rate of nasopharyngeal cancer increased by 26.3%, reaching 97.4%. The widespread application of this diagnostic kit means that more nasopharyngeal cancer patients will be detected early and receive effective treatment in a timely manner.

The China's Top 10 Pharmaceutical Biotechnology Advances selection is guided by the China Medicinal Biotech Association and hosted by the Journal Chinese Medicinal Biotechnology. The "Annual China's Top 10 Pharmaceutical Biotechnology Advances " event has been held for 10 consecutive years. The Top 10 Advances in 2024 cover three major areas, namely foundational technologies, clinical trials, and industrialization, comprehensively showcasing the breakthroughs and strengths of China's pharmaceutical biotechnology field.